ADMA Biologics Dirección
Dirección controles de criterios 3/4
El CEO de ADMA Biologics' es Adam Grossman , nombrado en Jan 2007, tiene una permanencia de 17.25 años. compensación anual total es $6.04M, compuesta por 12.4% salario y 87.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.3% de las acciones de la empresa, por valor de $19.46M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 11.8 años, respectivamente.
Información clave
Adam Grossman
Chief Executive Officer (CEO)
US$6.0m
Compensación total
| Porcentaje del salario del CEO | 12.4% |
| Permanencia del CEO | 17.3yrs |
| Participación del CEO | 1.3% |
| Permanencia media de la dirección | 2.3yrs |
| Promedio de permanencia en la Junta Directiva | 11.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02ADMA Biologics: Turning A Corner
Nov 20ADMA: Insiders Showing Their Cards
Nov 02ADMA Biologics: Recent Significant Developments And Their Implications For The Stock
Aug 22ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report
Aug 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$750k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$48m |
| Dec 31 2022 | US$3m | US$637k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$70m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$618k | -US$72m |
| Sep 30 2021 | n/a | n/a | -US$74m |
| Jun 30 2021 | n/a | n/a | -US$74m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$600k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$61m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$2m | US$536k | -US$48m |
| Sep 30 2019 | n/a | n/a | -US$56m |
| Jun 30 2019 | n/a | n/a | -US$59m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$2m | US$536k | -US$66m |
| Sep 30 2018 | n/a | n/a | -US$61m |
| Jun 30 2018 | n/a | n/a | -US$61m |
| Mar 31 2018 | n/a | n/a | -US$55m |
| Dec 31 2017 | US$3m | US$494k | -US$44m |
Compensación vs. Mercado: La compensación total ($USD6.04M) de Adam está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Adam ha aumentado mientras la empresa no es rentable.
CEO
Adam Grossman (46 yo)
17.3yrs
Permanencia
US$6,039,649
Compensación
Mr. Adam S. Grossman serves as Director at BioFlorida Inc since August 2021. He is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 17.3yrs | US$6.04m | 1.3% $ 19.7m | |
| Co-Founder & Vice Chairman of the Board | 17.3yrs | US$284.72k | 0.21% $ 3.2m | |
| COO & Senior VP of Compliance | no data | sin datos | 0.048% $ 731.5k | |
| Vice President of Marketing & Corporate Development | no data | sin datos | sin datos | |
| Executive Director of Human Resources | 2.3yrs | sin datos | sin datos | |
| Senior Director of Business Development & Corporate Strategy | no data | sin datos | sin datos |
2.3yrs
Permanencia media
46yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ADMA se considera experimentado (2.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 17.3yrs | US$6.04m | 1.3% $ 19.7m | |
| Co-Founder & Vice Chairman of the Board | 17.3yrs | US$284.72k | 0.21% $ 3.2m | |
| Independent Director | 11.9yrs | US$280.72k | 0.026% $ 390.5k | |
| Independent Chairman | 17.3yrs | US$290.22k | 0.023% $ 341.7k | |
| Independent Director | 2.5yrs | US$272.34k | 0.12% $ 1.8m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 11.8yrs | US$275.09k | 0.056% $ 853.5k | |
| Member of Scientific Advisory Board | 9.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 9.8yrs | sin datos | sin datos | |
| Independent Director | less than a year | US$231.12k | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
11.8yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de ADMA son experimentados ( 11.8 años antigüedad media).